Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674765 · ClinicalTrials.gov registry record · Phase 2
Seroquel for Frequent, Heavy Drinkers
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00674765: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00674765 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 156 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674765, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of quetiapine in reducing percent heavy drinking days and increasing percent abstinent days in alcohol dependent patients who are frequent heavy drinkers.
Interventions
- DRUG Placebo
- DRUG Seroquel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674765
The ClinicalTrials.gov registry entry for NCT00674765 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00674765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00674765 about?
NCT00674765 is a clinical study titled "Seroquel for Frequent, Heavy Drinkers". The purpose of this study is to examine the effects of quetiapine in reducing percent heavy drinking days and increasing percent abstinent days in alcohol dependent patients who are frequent heavy drinkers.
What is the current status of trial NCT00674765?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2008-01. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00674765?
The interventions under investigation include: Placebo (DRUG), Seroquel (DRUG).
Who is sponsoring clinical trial NCT00674765?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.